Actual problems of introduction of technologies and scientific developments in the field of medicine and healthcare were discussed by the industry representatives who participated in the online session “Life Sciences: explosive discoveries and trends”, organized in June by the newspaper “Vedomosti”.
Today, the Pharma industry remains one of the leaders in investing in R&D. Big Pharma Companies invest billions of dollars in the development of high-tech biomedical solutions aimed at increasing life expectancy and improving the quality of people’s lives. Dmitry Vlasov, medical Director, head of medical cluster CIS of Bayer, identified key areas that determine the development of Big Pharma: gene therapy, DNA editing; cell technologies; personalized medicine. He noted that the search for new molecules every year becomes more complicated: “R&D carried out, and the molecules, the market is seeing longer and longer”. As a result, the number of molecules remains approximately on the same level. Under these conditions a very important symbiosis of big Pharma, prospective University students and the state. According to experts, companies should look for young talents, to support start-up projects at an early stage. Such policies, in particular, by the company Bayer. Over the past 3 years she has supported 20 projects scientific activities, including the provision of access to international expertise and 9 financial.
Andrey Kaprin, Director of the “SMRC radiology” of Ministry of health of Russia, told about the difficulties faced by domestic developers of cancer drugs. He noted that just to create a molecule is not enough, we need a system that allows to implement the idea. “Our Institute created several targeted radiopharmaceuticals, but their implementation is delayed, – said General Director of “SMRC radiology”. – We need sponsors to conduct clinical investigations (CI)”. With regard to areas of research in the field of Oncology, several of them. The Institute focuses on the development of precision therapies (proton, ion, carbon) and the creation of combined drugs for the treatment of cancer.
Cyril kayem, senior Vice-President of the SKOLKOVO Foundation, referred to the international experience, stressing that “the world of business comes into play quite later stages KI”. This is because the survival of early projects does not exceed 2-3%. The first stage is supported by the government. In the second stage, when the scientific concept confirmed connect high-risk or seed funds, which are ready partly to co-invest with the state. And only on the 3rd stage of the innovation project start to support strategic investors – Big Pharma. But even after it connects, the probability that the product will reach the market is around 10-15%. I.e. risks remain.
“Investors play a very important role, agreed Alex Kluchenovich, CEO of Medicals Target Group. – Without them, small innovative enterprise to achieve the ultimate goal. Therefore, in addition to research activities we have lined up and engaged in a dialogue with the pharmaceutical industry to understand the perspectives of clinical application of our research.” We participated in startup competitions, and received the status of SKOLKOVO resident, which involves external independent expertise of projects”.